Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological products, has scheduled its fourth quarter and full year 2024 financial results announcement for March 21, 2025. The results will be released before market opening, followed by a conference call at 10:00am Eastern Time.
The company specializes in the commercialization of Ameluz® with the RhodoLED® lamp series for photodynamic therapy (PDT) of actinic keratosis (AK), which are pre-cancerous skin lesions. Biofrontera is also conducting clinical trials to expand these products' applications for treating non-melanoma skin cancers and moderate to severe acne.
Biofrontera Inc. (NASDAQ:BFRI), un'azienda biofarmaceutica specializzata in prodotti dermatologici, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per 21 marzo 2025. I risultati saranno resi noti prima dell'apertura del mercato, seguiti da una conferenza telefonica alle 10:00 ora orientale.
L'azienda si specializza nella commercializzazione di Ameluz® con la serie di lampade RhodoLED® per la terapia fotodinamica (PDT) della cheratosi attinica (AK), che sono lesioni cutanee precancerose. Biofrontera sta anche conducendo studi clinici per espandere le applicazioni di questi prodotti nel trattamento dei tumori cutanei non melanomatosi e dell'acne da moderata a grave.
Biofrontera Inc. (NASDAQ:BFRI), una compañía biofarmacéutica centrada en productos dermatológicos, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 21 de marzo de 2025. Los resultados se publicarán antes de la apertura del mercado, seguidos de una llamada de conferencia a las 10:00 a.m. hora del Este.
La compañía se especializa en la comercialización de Ameluz® con la serie de lámparas RhodoLED® para la terapia fotodinámica (PDT) de la queratosis actínica (AK), que son lesiones cutáneas precoces. Biofrontera también está llevando a cabo ensayos clínicos para ampliar las aplicaciones de estos productos en el tratamiento de cánceres de piel no melanoma y acné moderado a severo.
Biofrontera Inc. (NASDAQ:BFRI), 피부과 제품에 중점을 둔 생명공학 회사는 2024년 4분기 및 전체 연도 재무 결과 발표를 2025년 3월 21일로 예정했습니다. 결과는 시장 개장 전에 발표되며, 동부 표준시 기준 오전 10시에 컨퍼런스 콜이 이어질 예정입니다.
회사는 광역학 요법(PDT)을 위한 Ameluz®와 RhodoLED® 램프 시리즈의 상용화에 전문화되어 있으며, 이는 전암성 피부 병변인 광선각화증(AK) 치료에 사용됩니다. Biofrontera는 또한 비흑색종 피부암 및 중등도에서 심한 여드름 치료를 위한 이러한 제품의 적용을 확장하기 위한 임상 시험을 진행하고 있습니다.
Biofrontera Inc. (NASDAQ:BFRI), une entreprise biopharmaceutique spécialisée dans les produits dermatologiques, a programmé l'annonce de ses résultats financiers pour le quatrième trimestre et l'année complète 2024 pour le 21 mars 2025. Les résultats seront publiés avant l'ouverture du marché, suivis d'une conférence téléphonique à 10h00, heure de l'Est.
L'entreprise se spécialise dans la commercialisation de Ameluz® avec la série de lampes RhodoLED® pour la thérapie photodynamique (PDT) de la kératose actinique (AK), qui sont des lésions cutanées précancéreuses. Biofrontera mène également des essais cliniques pour étendre les applications de ces produits au traitement des cancers de la peau non mélanome et de l'acné modérée à sévère.
Biofrontera Inc. (NASDAQ:BFRI), ein biopharmazeutisches Unternehmen, das sich auf dermatologische Produkte spezialisiert hat, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 auf den 21. März 2025 terminiert. Die Ergebnisse werden vor Markteröffnung veröffentlicht, gefolgt von einer Telefonkonferenz um 10:00 Uhr Eastern Time.
Das Unternehmen spezialisiert sich auf die Vermarktung von Ameluz® mit der RhodoLED® Lampenserie für die photodynamische Therapie (PDT) von aktinischen Keratosen (AK), die präkanzeröse Hautläsionen sind. Biofrontera führt auch klinische Studien durch, um die Anwendung dieser Produkte zur Behandlung von nicht-melanomatischen Hautkrebsarten und von moderater bis schwerer Akne zu erweitern.
- None.
- None.
WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time.
Conference Call and Webcast Information
| Date | Friday, March 21, 2025 |
| Time | 10:00 AM Eastern Time |
| Dial In Numbers | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
| Webcast | Fourth Quarter and FY 2024 Financial Results and Business Update Conference Call |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
SOURCE: Biofrontera Inc.
FAQ
When will Biofrontera (BFRI) release its Q4 and full year 2024 earnings?
What time is BFRI's Q4 2024 earnings conference call?
What are the main products commercialized by Biofrontera (BFRI)?
What new treatment areas is BFRI exploring in clinical trials?
